Neuronal histamine in the hypothalamus suppresses food intake in rats.
Using probes to manipulate hypothalamic neuronal histamine, we report here that changes in neuronal histamine modulate physiological feeding behavior in rats. Infusion of alpha-fluoromethylhistidine (FMH), a "suicide" inhibitor of histidine decarboxylase (HDC), into the third cerebroventricle induced feeding in the early light phase when the histamine synthesis was most accelerated. FMH at an optimum 2.24 mumol dose elicited feeding in 100% of rats. Treatment of FMH specifically and selectively decreased concentration of histamine without affecting concentrations of catecholamines in the hypothalamus. Immediately before the dark phase, when the histamine synthesis was normally lower, FMH infusion did not affect feeding-related parameters such as meal size, meal duration or latency to eat. Conversely, thioperamide, which facilitates both synthesis and release of neuronal histamine by blocking presynaptic autoinhibitory H3 receptors, significantly decreased food intake after infusion of a 100-nmol dose into the third cerebroventricle. The effect of thioperamide was abolished with i.p. injection of 26 mumol/kg chlorpheniramine, an H1antagonist. FMH at 224 nmol was microinfused bilaterally into the feeding-related nuclei in the hypothalamus. The ventromedial nucleus (VMH) and the paraventricular nucleus (PVN), but not the lateral hypothalamus, the dorsomedial hypothalamus or the preoptic anterior hypothalamus were identified as the active sites for the modulation. Neuronal histamine may convey suppressive signals of food intake through H1 receptors in the VMH and the PVN with diurnal fluctuation.
Ookuma
K
K
Department of Internal Medicine I, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Sakata
T
T
Fukagawa
K
K
Yoshimatsu
H
H
Kurokawa
M
M
Machidori
H
H
Fujimoto
K
K
D000818:Animals; D001665:Binding Sites; D002395:Catecholamines / Q000378:metabolism; D002552:Cerebral Ventricles; D004435:Eating / Q000502:physiology*; D005246:Feedback; D006632:Histamine / Q000378:metabolism / Q000502:physiology*; D006633:Histamine Antagonists; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors*; D007031:Hypothalamus / Q000502:physiology*; D007263:Infusions, Parenteral; D008297:Male; D008762:Methylhistidines / Q000494:pharmacology*; D009474:Neurons / Q000502:physiology*; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D002395:Catecholamines; D006633:Histamine Antagonists; D008762:Methylhistidines; D010880:Piperidines; C028309:alpha-fluoromethylhistidine; D006632:Histamine; D006640:Histidine Decarboxylase; C052075:thioperamide